| Christopher D Coccia, DO | |
|
408 Clark St Ne, Cullman, AL 35055-1953 | |
| (256) 734-3202 | |
| (256) 734-4668 |
| Full Name | Christopher D Coccia |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 27 Years |
| Location | 408 Clark St Ne, Cullman, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083695696 | NPI | - | NPPES |
| 51522970 | Other | AL | BCBS OF ALABAMA |
| 051522970 | Medicaid | AL | |
| 631165851 | Other | AL | TAX ID |
| E873 | Other | AL | MEDICARE GROUP# |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | DO847 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Gentiva Hospice - Huntsville | Huntsville, AL | Hospice |
| Cullman Regional Medical Center | Cullman, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Birmingham Internal Medicine Associates, Llc | 1658341193 | 121 |
News Archive
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
FDA today published a final rule establishing donor eligibility criteria for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) to help prevent the transmission of communicable disease when these products are transplanted.
New figures released today show that the treatment received by patients for oesophageal cancer, and its precursor condition Barrett's oesophagus, varies significantly across England.
The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.
In this new study researchers at the UC Davis MIND Institute, show there are multiple biological subtypes of autism including likely differences between males and females. They looked at 114 children with autism spectrum disorder between the ages of 2 and 4 and compared them with 66 healthy children of the same age. Of the 114 with the disorder, 54% had regressive autism and 46% had non-regressive autism.
› Verified 7 days ago
| Entity Name | Birmingham Internal Medicine Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598796542 PECOS PAC ID: 1658341193 Enrollment ID: O20040730000432 |
News Archive
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
FDA today published a final rule establishing donor eligibility criteria for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) to help prevent the transmission of communicable disease when these products are transplanted.
New figures released today show that the treatment received by patients for oesophageal cancer, and its precursor condition Barrett's oesophagus, varies significantly across England.
The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.
In this new study researchers at the UC Davis MIND Institute, show there are multiple biological subtypes of autism including likely differences between males and females. They looked at 114 children with autism spectrum disorder between the ages of 2 and 4 and compared them with 66 healthy children of the same age. Of the 114 with the disorder, 54% had regressive autism and 46% had non-regressive autism.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher D Coccia, DO 503 Clark St Ne, Cullman, AL 35055-1921 Ph: (256) 739-1759 | Christopher D Coccia, DO 408 Clark St Ne, Cullman, AL 35055-1953 Ph: (256) 734-3202 |
News Archive
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
FDA today published a final rule establishing donor eligibility criteria for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) to help prevent the transmission of communicable disease when these products are transplanted.
New figures released today show that the treatment received by patients for oesophageal cancer, and its precursor condition Barrett's oesophagus, varies significantly across England.
The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.
In this new study researchers at the UC Davis MIND Institute, show there are multiple biological subtypes of autism including likely differences between males and females. They looked at 114 children with autism spectrum disorder between the ages of 2 and 4 and compared them with 66 healthy children of the same age. Of the 114 with the disorder, 54% had regressive autism and 46% had non-regressive autism.
› Verified 7 days ago
Dr. Ryan Glenn Mcmorries, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1912 Al Highway 157, Cullman, AL 35058 Phone: 256-737-2000 | |
Thomas W Montgomery, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 408 Clark St Ne, Cullman, AL 35055 Phone: 256-734-3202 Fax: 256-734-4668 | |
Tyler James Rushforth, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1935 Alabama Highway 157, Suite C, Cullman, AL 35058 Phone: 256-297-3030 Fax: 256-297-3301 | |
Lauren C Robinson, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 1948 Al Highway 157 Ste 450, Cullman, AL 35058 Phone: 256-735-5075 Fax: 256-962-5598 | |
Justin Rushing, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1750 Al Highway 157, Cullman, AL 35058 Phone: 256-427-2427 | |
Michael L Schendel, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 408 Clark St Ne, Cullman, AL 35055 Phone: 256-734-3202 Fax: 256-734-4668 |